TIDMACPH 
 
 
   Acacia Pharma Group plc 
 
   Issue of Equity on Exercise of Options/Vesting of Performance Share 
Awards 
 
   Cambridge, UK and Indianapolis, US -- 4 February 2021: Acacia Pharma 
Group plc ("Acacia Pharma", the "Group" or the "Company") (EURONEXT: 
ACPH), a hospital pharmaceutical company focused on the development and 
commercialization of new products aimed at improving the care of 
patients undergoing significant treatments such as surgery, other 
invasive procedures or cancer chemotherapy, announces announces that 
application has been made to Euronext Brussels for the admission of the 
31,500 Ordinary Shares of GBP0.02 each (the "New Ordinary Shares") to 
trading on Euronext Brussels ("Admission") to satisfy the exercise of 
options granted under the Company's Enterprise Management Incentive 
Share Option Plan.  The New Ordinary Shares will rank pari passu in all 
respects with the Company's existing Ordinary Shares in issue. 
 
   Following issue of the New Ordinary Shares, the Company's total issued 
share capital consists of 89,659,451 Ordinary Shares with one voting 
right per share. The Company does not hold any Ordinary Shares in 
Treasury. Therefore, following the issue of the New Ordinary Shares, the 
total number of voting rights in the Company is 89,659,451. 
 
   Contacts 
 
 
 
 
Acacia Pharma Group plc                          International Media 
 Mike Bolinder, CEO                               Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                              Dible 
 +44 1223 919760 / +1 317 505 1280                Citigate Dewe Rogerson 
 mailto:IR@acaciapharma.com IR@acaciapharma.com   +44 20 7638 9571 
                                                  mailto:acaciapharma@citigatedewerogerson.com 
                                                  acaciapharma@citigatedewerogerson.com 
-----------------------------------------------  --------------------------------------------- 
US Investors                                     Media in Belgium and the Netherlands 
 LifeSci Advisors                                 Chris Van Raemdonck 
 Irina Koffler                                    +32 499 58 55 31 
 +1 917-734-7387                                  mailto:chrisvanraemdonck@telenet.be 
 mailto:ikoffler@lifesciadvisors.com              chrisvanraemdonck@telenet.be 
 ikoffler@lifesciadvisors.com 
-----------------------------------------------  ---------------------------------------------

(END) Dow Jones Newswires

February 04, 2021 01:00 ET (06:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Acacia Pharma Charts.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Acacia Pharma Charts.